MARKET WIRETradingKey • 1d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
Why SNOA Stock Traded Steady Today — RQD Quant Desk Flash
$1.10 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.10
Sonoma Pharmaceuticals Inc. (SNOA) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $5.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SNOA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SNOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.10 (0.00% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, SNOA ranks #657 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SNOA compare to TNON and INBS in the Health Care sector?
▼
Within the Health Care sector (Medical/Dental Instruments), SNOA carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 38.0%, and ROIC of -35.0%. By comparison, TNON (Tenon Medical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and INBS (Intelligent Bio Solutions Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M). Among the 5-stock peer group, SNOA leads on earnings multiple (N/A) while SNOA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SNOA?
▼
Per SNOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001367083), Sonoma Pharmaceuticals Inc. generated $19.5M in revenue (+36.7% YoY), $3.2K in net income, and -$4.1M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.10 (-0.19%)🧬 Disciplined Float (+0.16% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR RQD RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SNOA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY SNOA SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (38% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
▲ #2 Bullish Driver: Insider Conviction & Share Dilution+7/20 pts (21% of score)
SEC Form 4 / 13F Thermometer: 35% Net Buy • Disciplined Float (+0.16% YoY Shares)
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.16-1.7% Next Q
42
Q2 (-2Q)Grade E$1.14+0% Next Q
39
Q3 (-1Q)Grade E$1.14-3.5% Next Q
37
CurrentGrade E$1.10-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SNOA Turnaround Squeeze
While SNOA currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.23) and Max Pain ($1.16) forces dealer call-delta covering toward $4.15.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.16% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SNOA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SNOA Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SNOA Stock Traded Steady Today — RQD Quant Desk Flash
Sonoma Pharmaceuticals Inc. (SNOA) slipped 0.00% to $1.10, trading at 8% of its 52-week range ($0.85 – $3.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 8% of its 52-week range ($0.85 – $3.95) with RSI-14 at 42.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.10 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 38% gross margin and $0 annual free cash flow.
Live SNOA Headlines & Catalysts
CATALYSThttps://www.dars.gov.et/ • 1d ago
Sonoma Pharmaceuticals Q2 2026 Earnings: Narrow EPS Miss Keeps Shares Under Pressure - Dividend Growth Analysishttps://www.dars.gov.et/ report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Unusual Volume Stocks & Volume Spikes TodayTradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMugglehead Investment Magazine • 2d ago
Kane Biotech signs Canadian distribution agreement for revyve wound careMugglehead Investment Magazine report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Complete U.S. Stocks List: Prices, Performance and Key DataTradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 2d ago
Top U.S. Stock Losers: Biggest Price DeclinesTradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SNOA)
- ✓Walkthrough of SNOA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SNOA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.57%🛡️ HOLDING TREND SUPPORT
2026-11-04O $1.10H $1.10L $1.10C $1.10VOL 42.2K
RES: $1.51SUP: $1.07SMA50: $1.23SMA200: $1.67
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SNOA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. +36.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on SNOA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SNOA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SNOA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SNOA)
Health Care Rank #657 of 1015
⚔️ TNON vs SNOA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SNOA vs. TNON, INBS, NVNO, WOK)
Industry: Medical/Dental Instruments (120 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Sonoma Pharmaceuticals Inc. (SNOA) ranks #657 by composite RQD confidence (34/100, grade E) and #933 by equity capitalization ($5.3M). Within this direct 5-issuer industry benchmark cohort, SNOA leads on earnings valuation at N/A trailing P/E, while SNOA leads on capital efficiency and profitability with -35.0% ROIC and 38.0% gross margin. WOK currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with SNOA at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SNOA
ACTIVE
Sonoma Pharmaceuticals Inc. | E | 34/100 | — | 38.0% | -35.0% | 0.00% | $5.3M | Benchmark Subject |
| TNON Tenon Medical Inc. | E | 30/100 | — | 59.8% | -35.0% | -5.85% | $5.2M | /tnon-vs-snoa → |
| INBS Intelligent Bio Solutions Inc. | E | 27/100 | — | 40.8% | -35.0% | -5.68% | $5.5M | /inbs-vs-snoa → |
| NVNO enVVeno Medical Corporation | E | 33/100 | — | — | -35.0% | +2.08% | $4.8M | /nvno-vs-snoa → |
| WOK WORK Medical Technology Group LTD (Class A) | D | 51/100 | — | — | — | 0.00% | $4.5M | /wok-vs-snoa → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001367083 ↗In its most recent audited fiscal period (FY2025, filed 2026-03-31), Sonoma Pharmaceuticals Inc. (SNOA) reported GAAP revenue of $19.5M (+36.7% vs. FY2024 revenue of $14.3M , and +53.3% cumulative change since FY2023) , GAAP net income of $3.2K, operating cash flow of -$3.9M, and free cash flow of -$4.1M (-2355.4% YoY). On the balance sheet, SNOA closed FY2025 with $13.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $19.5M | $3.2K | -$3.9M | -$4.1M | $13.6M | — |
| FY2024 (FY) | 2025-03-31 | $14.3M | $3.5K | -$88.0K | -$168.0K | $13.7M | — |
| FY2023 (FY) | 2024-03-31 | $12.7M | $4.8K | -$2.4M | -$2.4M | — | — |
3. SNOA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SNOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Sonoma Pharmaceuticals Inc. (NASDAQ: SNOA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.10 (0.00% 1D, market cap $5.3M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 7/20. Across 1015 tracked Health Care issuers, SNOA ranks #657 in composite RQD confidence.
How does SNOA compare to TNON and INBS in the Health Care sector?
Within the Health Care sector (Medical/Dental Instruments), SNOA carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of 38.0%, and ROIC of -35.0%. By comparison, TNON (Tenon Medical Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $5.2M) and INBS (Intelligent Bio Solutions Inc.) posts a E grade (27/100 RQD, P/E N/A, ROIC -35.0%, cap $5.5M). Among the 5-stock peer group, SNOA leads on earnings multiple (N/A) while SNOA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SNOA?
Per SNOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001367083), Sonoma Pharmaceuticals Inc. generated $19.5M in revenue (+36.7% YoY), $3.2K in net income, and -$4.1M in free cash flow against $13.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SNOA trading relative to its 50-day, 200-day, and 52-week technical levels?
SNOA last traded at $1.10 (0.00% on volume of 42,243 shares), positioning the stock -10.57% below its 50-day simple moving average ($1.23) and -34.13% below its 200-day simple moving average ($1.67). Across its 52-week range of $0.85 to $3.95, SNOA sits at the 8.1% percentile with a 14-day RSI of 42.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.24).
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ SEC XBRL & RQD VERIFIED
SNOA — Sonoma Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-03-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Sonoma Pharmaceuticals Inc. (SNOA) earns a live Roarable RQD composite score of 34/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.10 (0.00% 1D, market capitalization $5.3M).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 38.0%, operating margin of -12.6%, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (7/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (6/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 4/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Sonoma Pharmaceuticals Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Medical/Dental Instruments industry. The market capitalization is $0.0B. — The specific products, customer base, and revenue model are not described in the provided sources.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Sonoma Pharmaceuticals Inc. (SNOA) reported $19.5M in annual revenue (up from $14.3M in FY2024, +36.7% YoY) and $3.2K in GAAP net income. Over the multi-year SEC filing window from FY2023 ($12.7M revenue, $4.8K net income) through FY2025, SNOA scaled operating cash flow to -$3.9M and free cash flow to -$4.1M, backed by $13.6M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 34/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.85 – $3.95 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -12.6% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Operating in Medical/Dental Instruments (Health Care), SNOA carries a macro regime beta of 1.00 and gross margin of 38.0%.
- Key Question #1: Can SNOA sustain or expand its -12.6% operating margin and -35.0% ROIC against Medical/Dental Instruments peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $19.5M and free cash flow of -$4.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is SNOA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
SNOA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Sonoma Pharmaceuticals Inc. (SNOA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE TradingKey • 1d ago
Most Active Stocks Today: U.S. Market TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST https://www.dars.gov.et/ • 1d ago
Sonoma Pharmaceuticals Q2 2026 Earnings: Narrow EPS Miss Keeps Shares Under Pressure - Dividend Growth Analysis https://www.dars.gov.et/ report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Unusual Volume Stocks & Volume Spikes Today TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Mugglehead Investment Magazine • 2d ago
Kane Biotech signs Canadian distribution agreement for revyve wound care Mugglehead Investment Magazine report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Complete U.S. Stocks List: Prices, Performance and Key Data TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 2d ago
Top U.S. Stock Losers: Biggest Price Declines TradingKey report covering Sonoma Pharmaceuticals Inc. (SNOA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SNOA Bull vs. Bear Conversation Board — What's Your Call at $1.10?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SNOA 🐻 33% BEARISH CONVICTION
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH
🎯 Target: $1.40 (+27.3%)
📌 Pinned Debate Revenue grew from $12.7M in FY 2023 to $19.5M in FY 2025 and the forensic balance sheet pillar scored 13 of 20, the strongest in the ra
Revenue grew from $12.7M in FY 2023 to $19.5M in FY 2025 and the forensic balance sheet pillar scored 13 of 20, the strongest in the rating.. When you look under the hood at SNOA, Fundamental Cash Engine is 5/20 with 38.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $3.97. My 12M target is $1.40.
RetailWhale_TX 🐂 BULL
Both sides have a point here — SNOA's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH
🎯 Target: $0.95 (-13.6%)
Spot @ $1.10 ROIC of -35%, a 0% FCF yield, and operating losses in every reported period leave the cash engine unproven while cash fell to $2.6M.
ROIC of -35%, a 0% FCF yield, and operating losses in every reported period leave the cash engine unproven while cash fell to $2.6M.. Look at the math on SNOA: paying current EV/EBITDA multiples for -35.0% ROIC and -12.6% operating margins leaves zero margin of safety if Medical/Dental Instruments demand softens. I'd wait for a retest of $0.97 before getting long.